Table 1 Patient characteristics and presence of mutations by group
From: Genetic analysis of uterine lavage fluids to identify women at high risk of endometrial cancer
Characteristic | Overall, N = 2571 | Controls, N = 881 | EIN, N = 801 | EC, N = 891 | p-value2 |
|---|---|---|---|---|---|
Age (years) | 56 (48, 67) | 47 (44, 51) | 53 (48, 62) | 66 (59, 73) | < 0.001 |
BMI (kg/m2) | 30 (25, 36) | 29 (23, 31) | 31 (25, 41) | 31 (27, 35) | 0.006 |
Parity | 0.589 | ||||
0 | 24 (15.8%) | 10 (19.2%) | 6 (14.6%) | 8 (13.6%) | |
1 | 33 (21.7%) | 10 (19.2%) | 7 (17.1%) | 16 (27.1%) | |
2 | 80 (52.6%) | 24 (46.2%) | 24 (58.5%) | 32 (54.2%) | |
3 | 14 (9.2%) | 7 (13.5%) | 4 (9.8%) | 3 (5.1%) | |
4 | 1 (0.7%) | 1 (1.9%) | 0 (0.0%) | 0 (0.0%) | |
Hormonal contraceptives | 0.001 | ||||
No | 112 (74.2%) | 34 (65.4%) | 27 (65.9%) | 51 (87.9%) | |
Yes | 37 (24.5%) | 18 (34.6%) | 14 (34.1%) | 5 (8.6%) | |
Not known | 2 (1.3%) | 0 (0.0%) | 0 (0.0%) | 2 (3.4%) | |
Hypertension | 0.002 | ||||
No | 78 (51.3%) | 36 (69.2%) | 21 (51.2%) | 21 (35.6%) | |
Yes | 74 (48.7%) | 16 (30.8%) | 20 (48.8%) | 38 (64.4%) | |
DM | 0.070 | ||||
No | 125 (82.2%) | 47 (90.4%) | 36 (87.8%) | 42 (71.2%) | |
DM I | 1 (0.7%) | 0 (0.0%) | 0 (0.0%) | 1 (1.7%) | |
DM II | 25 (16.4%) | 5 (9.6%) | 5 (12.2%) | 15 (25.4%) | |
Not known | 1 (0.7%) | 0 (0.0%) | 0 (0.0%) | 1 (1.7%) | |
PAD3 | 0.007 | ||||
No | 130 (85.5%) | 48 (92.3%) | 38 (92.7%) | 44 (74.6%) | |
Yes | 21 (13.8%) | 3 (5.8%) | 3 (7.3%) | 15 (25.4%) | |
Not known | 1 (0.7%) | 1 (1.9%) | 0 (0.0%) | 0 (0.0%) | |
Any mutation NGS | 0.501 | ||||
No | 100 (38.9%) | 32 (36.4%) | 29 (36.2%) | 39 (43.8%) | |
Yes | 157 (61.1%) | 56 (63.6%) | 51 (63.7%) | 50 (56.2%) | |
POLE EDM4 | 4 (1.6%) | 1 (1.1%) | 1 (1.3%) | 2 (2.2%) | > 0.999 |
AKT1 | 6 (2.3%) | 2 (2.3%) | 2 (2.5%) | 2 (2.2%) | > 0.999 |
APC | 23 (8.9%) | 6 (6.8%) | 10 (12.5%) | 7 (7.9%) | 0.395 |
ARID1A | 58 (22.6%) | 24 (27.3%) | 16 (20.0%) | 18 (20.2%) | 0.428 |
ARID5B | 17 (6.6%) | 9 (10.2%) | 2 (2.5%) | 6 (6.7%) | 0.132 |
ATM | 50 (19.5%) | 22 (25.0%) | 16 (20.0%) | 12 (13.5%) | 0.152 |
CDKN2A | 6 (2.3%) | 2 (2.3%) | 2 (2.5%) | 2 (2.2%) | > 0.999 |
CTNNB1 | 21 (8.2%) | 7 (8.0%) | 5 (6.2%) | 9 (10.1%) | 0.655 |
EGFR | 5 (1.9%) | 2 (2.3%) | 2 (2.5%) | 1 (1.1%) | 0.745 |
FBXW7 | 16 (6.2%) | 8 (9.1%) | 5 (6.2%) | 3 (3.4%) | 0.285 |
FGFR2 | 15 (5.8%) | 3 (3.4%) | 4 (5.0%) | 8 (9.0%) | 0.298 |
HRAS | 1 (0.4%) | 1 (1.1%) | 0 (0.0%) | 0 (0.0%) | 0.654 |
KRAS | 35 (13.6%) | 15 (17.0%) | 16 (20.0%) | 4 (4.5%) | 0.007 |
NRAS | 3 (1.2%) | 1 (1.1%) | 0 (0.0%) | 2 (2.2%) | 0.776 |
PIK3CA | 40 (15.6%) | 18 (20.5%) | 12 (15.0%) | 10 (11.2%) | 0.236 |
PIK3R1 | 26 (10.1%) | 9 (10.2%) | 8 (10.0%) | 9 (10.1%) | 0.999 |
POLD1 | 14 (5.4%) | 6 (6.8%) | 3 (3.8%) | 5 (5.6%) | 0.697 |
POLE | 30 (11.7%) | 11 (12.5%) | 9 (11.2%) | 10 (11.2%) | 0.957 |
PPP2R1A | 11 (4.3%) | 6 (6.8%) | 3 (3.8%) | 2 (2.2%) | 0.313 |
PTEN | 71 (27.6%) | 25 (28.4%) | 23 (28.7%) | 23 (25.8%) | 0.896 |
RB1 | 12 (4.7%) | 5 (5.7%) | 2 (2.5%) | 5 (5.6%) | 0.572 |
RPL22 | 19 (7.4%) | 6 (6.8%) | 8 (10.0%) | 5 (5.6%) | 0.536 |
TP53 | 12 (4.7%) | 7 (8.0%) | 4 (5.0%) | 1 (1.1%) | 0.081 |